Cerus (CERS) Misses Q3 EPS by 1c

Go back to Cerus (CERS) Misses Q3 EPS by 1c

Cerus Corporation Announces Third Quarter 2019 Results

October 30, 2019 4:03 PM EDT

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2019.

Recent developments and highlights include:

FDA issued its final guidance document on strategies to mitigate the risk of bacterial contamination in transfused platelet components Total third quarter revenue of $22.8 million Quarterly product revenue of $18.0 million, a 17% increase compared to the prior year quarter Government contract revenue of $4.8 million Worldwide demand for INTERCEPT continued to increase; calculated number of treatable platelet doses... More